Cagrilintide Plus Semaglutide: CagriSema Trials and Evidence Limits
A combination claim needs combination evidence. Our assessment is that cagrilintide plus semaglutide now has an important clinical trial record, but the most useful account includes both successful placebo comparisons and the comparison target that was missed. Reading only the largest weight-loss headline gives an incomplete answer.
This profile examines selected original CagriSema studies and clearly identified sponsor updates. It is written for readers who want to understand the research behind a peptide combination, including what the results can and cannot establish about a different preparation offered online.
What does CagriSema refer to?
The clinical program uses CagriSema for the combination of cagrilintide, an amylin analogue, and semaglutide, a GLP-1-based medicine. Novo Nordisk describes the tested product as a fixed-dose combination. Sponsor’s description.
Our recommendation is to distinguish that named development program from any product that merely lists the same two ingredients. Require documentation of the actual preparation, intended use and evidence supporting the comparison. A matching pair of names does not answer those questions.
For the individual ingredients, read the cagrilintide profile and semaglutide profile. This page focuses on the combined intervention and its clinical comparisons.
The early combination research
A phase 1b trial studied multiple cagrilintide dose groups added to semaglutide. Its control groups received placebo with semaglutide, so the comparison was about adding cagrilintide to that background treatment. Safety, tolerability, drug exposure and weight-related measurements were assessed. Original phase 1b report.
Our interpretation: the comparator matters even in a small early study. Describe the background treatment instead of implying that the control group received no active medicine. Early results can justify larger research without settling long-term effectiveness or the complete safety profile.
A subsequent 92-person phase 2 trial in type 2 diabetes tested the combination against each component over 32 weeks. Its primary HbA1c comparison favored the combination over cagrilintide, but did not establish superiority over semaglutide, P = .075. Original phase 2 study.
Our interpretation: keep the primary result intact even when other findings are encouraging. A favorable weight result should not be used to rewrite an unsuccessful glycemic comparison. Our negative-study guide explains why endpoint priority matters.
An evidence map for the combination
This original map is a reading aid. It does not show measured treatment effects or rank the studies by quality.
Does the combination improve the chosen outcome?
Keep the population visible.
What does adding the second ingredient contribute?
Check the actual endpoint.
Was the planned comparison target achieved?
Read beyond the weight-loss headline.
Use this map when someone calls a combination “better.” Ask which card contains the evidence for that statement and what the comparison actually measured.
REDEFINE 1: weight management without diabetes
REDEFINE 1 randomized 3,417 adults without diabetes for 68 weeks. The treatment-policy analysis estimated weight change of -20.4% with the combination versus -3.0% with placebo. Gastrointestinal adverse events occurred in 79.6% versus 39.9%, mainly transient and mild or moderate. Original REDEFINE 1 trial.
Our interpretation: this supports substantial average weight reduction in the trial setting. Preserve the analysis definition and include tolerability alongside efficacy. The percentage should not become a guarantee for every participant, a short-term expectation or a claim about an unrelated blend.
For a comparison with monotherapy, consult the component arms rather than importing a result from a different trial. The cagrilintide profile discusses that ingredient’s own result; neither ingredient should be assigned the entire combination effect.
REDEFINE 2: weight management with type 2 diabetes
REDEFINE 2 randomized 1,206 participants with type 2 diabetes to the combination or placebo for 68 weeks. Mean weight change was -13.7% versus -3.4% in the treatment-policy analysis. Gastrointestinal adverse events were reported in 72.5% versus 34.4%. Original REDEFINE 2 publication.
Our interpretation: report this as a separate population, not as a contradictory version of the preceding trial. We would not merge the two studies into one universal expected percentage. A reader with a diabetes question should see the relevant diabetes evidence directly.
Also ask whether a quoted comparison addresses weight, glycemic control or another endpoint. Those questions may require different analyses, and a strong result for one does not remove the need to examine the others.
REIMAGINE 2: the newer diabetes comparison
REIMAGINE 2’s primary efficacy analysis compared the combination at 2.4 mg of each ingredient with semaglutide 2.4 mg. At 68 weeks, mean HbA1c change was -1.91 versus -1.75 percentage points, an estimated difference of -0.16, with a 95% confidence interval of -0.27 to -0.05, P = .0035. Original 2026 REIMAGINE 2 report.
Our interpretation: this is a successful primary glycemic comparison, and its magnitude should be reported as clearly as its statistical significance. Do not replace the actual incremental difference with a vague claim of dramatically superior diabetes control.
The earlier phase 2 result and this larger phase 3 result belong in the same research history. Our assessment is that evidence should be updated when a later study adds information, while retaining enough context to show which question the newer trial resolved.
REDEFINE 4: the comparison target that was missed
In its February 2026 announcement, Novo Nordisk reported that the 809-person, open-label REDEFINE 4 trial did not meet its primary noninferiority target against tirzepatide at 84 weeks. Sponsor-reported efficacy estimates were 23.0% weight loss with CagriSema versus 25.5% with tirzepatide; treatment-regimen estimates were 20.2% versus 23.6%. Sponsor announcement.
Our interpretation: substantial weight loss and a missed comparison target can coexist. Do not remove the failure from the summary because the absolute weight change sounds impressive. Equally, do not rewrite a missed noninferiority target as proof that the combination has no effect.
These are sponsor-reported results here, not a substitute for a fully appraised peer-reviewed trial report. Keep that source type visible. The tirzepatide profile provides context for the comparator without treating different studies as interchangeable.
Why there can be more than one weight-loss number
Our recommended habit is to copy the analysis label together with the result. Ask what the estimate assumes about continued treatment, interruptions, other interventions and missing observations. Avoid selecting whichever analysis gives the most favorable headline.
For a comparison, use like-for-like analyses within the same study whenever possible. If you need to discuss different studies, spell out the differences in participants, duration and protocol before offering a judgment. Our trial-comparison guide explains that process in plain language.
Approval, cardiovascular claims and remaining questions
Novo Nordisk’s second-quarter 2026 presentation described a US decision on the obesity application as expected in the fourth quarter of 2026. It also described REDEFINE 3 as a cardiovascular-outcomes study whose results were still expected later. Sponsor’s current development update.
Our interpretation: an expected regulatory decision is not approval, and an outcomes study in progress is not a completed cardiovascular benefit finding. Do not automatically transfer every approved semaglutide indication to a combination containing semaglutide.
FDA’s current communication states that cagrilintide is not a component of an FDA-approved drug and cannot be used in compounding under federal law. FDA communication checked September 13, 2026.
Use a clinician to discuss approved options, eligibility and treatment planning. This profile does not establish that a research product is appropriate for personal use.
What a responsible safety discussion should include
Our assessment is that the gastrointestinal-event findings above are part of the core evidence, not a footnote. A benefit assessment should also ask about serious events, discontinuation, duration of follow-up and the selection of participants. A limited article summary cannot replace the full safety record or an individualized clinical assessment.
Do not assume that an adverse-effect list for one ingredient completely describes the combination. For a research claim, identify the exact product and study. For an actual symptom or medication question, consult a clinician or pharmacist rather than using a trial average to decide whether to continue.
Can the trial validate a different premixed vial?
Our recommendation is to require a separate chain of evidence for the supplied preparation. Ask how identity, amount, formulation, quality and handling were established. A citation to a CagriSema trial answers a clinical research question; it should not be used to skip those product-specific questions.
The blend-evidence guide provides a structured way to evaluate component claims and combination claims. The practical standard is simple: make the statement no broader than the preparation, population and outcome that were actually evaluated.
Sources and editorial scope
This selected narrative review was checked September 13, 2026. Original abstracts and publication text support the trial summaries. REDEFINE 1’s publisher PDF and an original REIMAGINE 2 PDF mirror were checked where direct database access was incomplete. REDEFINE 4 and development timelines are explicitly attributed sponsor communications. This is not a systematic review or medical prescription.